Weltruza FDA Approval: What PMHNPs Need to Know
Weltruza, the first monthly subcutaneous olanzapine LAI, drops the 3-hour observation. What PMHNPs need on dosing, PDSS, candidates, and metabolic monitoring.
Read More →HHS wants psychiatric medications reviewed more often, but its letter binds no one. What PMHNPs should change in consent, charting and Medicare billing.

What do you do when the federal government suddenly tells you to reconsider prescribing the very medications that might be keeping your patients alive? Yeah, that is a terrifying moment for any practitioner. Right. I mean, on May 4th, 2026, this massive alarm just went off in the psychiatric community. Headlines everywhere were announcing this sweeping new federal push to combat psychiatric overprescribing.
And if you are a psychiatric nurse practitioner, like a PMHNP, you're the one patients immediately look to when that alarm rings. Exactly. They see the news, they panic, and they call you. And the pressure in those moments is just immense. You have these national political figures taking to the airwaves demanding immediate changes to how psychiatric drugs are managed.
It creates this atmosphere of an impending clinical emergency, right? Oh, absolutely. You assume the ground rules of your practice have just shifted overnight. That is exactly why we are dedicating this deep dive to cutting through the noise. We really need to.
Yeah. So whether you are an early career PMH NP facing these questions in the clinic today, or just a curious learner wanting to look behind the curtain at how mental health care actually adapts to national policy, we are speaking directly to you. Because the reality is very different from the news cycle. Right. And to do this, we're using a highly practical framework laid out in an article called, Federal Deep Prescribing Push, What PMHNPs Should Do Now.
And that was written by Lindsay Hill from the Psych NP Fellowship. Lindsay's approach is incredibly grounding because… You know, she just ignores all the social media chatter and focuses entirely on the primary documents. Which is so refreshing. It really is.
So we're going to walk through the actual May 4th HHS Dear Colleague letter, the corresponding billing guidelines from CMS and the clinical consensus. Because the objective is to give you a clear, actionable roadmap based on what is legally and medically on paper. Okay, let's unpack this. Let's start with the gap between the political speeches and the reality on your desk as of November 1st, 2026. Yeah, because reading Lindsay's breakdown of what actually exists is a bit of a shock.
It really is. The contrast is stark. Right. If you go searching for this sweeping new federal mandate, you're only going to find two things. First, a four-page dear colleague letter signed by the leaders of several federal agencies.
Like SAMHSA. Yeah, SAMHSA, which handles substance abuse and mental health, and CMS, the agency that runs Medicare and Medicaid. And then second, you'll find a three-page CMS FAQ document focused entirely on billing. But wait, that leaves a massive void. I mean, weren't there supposed to be clinical webinars over the summer?
Yep. What about that technical expert panel in July? Weren't they supposed to release specific guidelines on how to physically taper these drugs? Those remain completely unfulfilled promises. Wow, really?
Yeah, there are no published panel findings or step-by-step federal tapering manuals available yet. None. So anyone claiming they have the quote-unquote new federal rules for tapering is just selling smoke? Exactly. The guidance simply does not exist yet.
The text of the letter itself is another fascinating reality check. I mean, you had high-profile figures like HHS Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz publicly stating this action plan would require informed consent and shared decision-making for all psychiatric prescriptions.
Right, they used very strong language. But the actual text of the Dear Colleague letter does not use the word require. The operative verb is just encourages. It just encourages clinicians to review regimens. It encourages shared decision-making.
Legally and clinically, the distance between a mandate and a strong suggestion is a chasm. It really is. It reminds me of driving down the highway and seeing a massive billboard for a zero percent interest car loan in huge bold letters. It grabs your attention, you pull over. But then you read the fine print.
Exactly. You sit down, you read the legally binding fine print of the actual contract. And that bold promise comes with a dozen caveats. The political headlines were the billboard, and this four-page letter is the fine print. And regardless of the politics driving those headlines, the clinical reality for practitioners is what actually matters today.
And we have to look at this strictly objectively. Right, politics aside, what does this mean for the patient? Exactly. And that clinical reality includes fierce pushback from major medical institutions. The American Psychiatric Association argued that framing the current landscape primarily as an overprescribing crisis is dangerously reductionist.
Because they maintain the real crisis is systemic, right? Right. They're pointing to severe workforce shortages, disappearing psychiatric beds, and massive insurance barriers to talk therapy. And the American Foundation for Suicide Prevention issued an equally stark warning. They pointed out that abruptly stopping psychiatric medications or tapering them without intense clinical supervision severely elevates suicide risk and guarantees symptom relapse.
The biology behind that warning is crucial to understand. When a patient takes a psychiatric medication for years, their brain alters its physical structure to achieve a new equilibrium. So receptors upregulate or downregulate. Right. If you suddenly remove that chemical support because of a scary news headline, you aren't just returning the brain to its baseline.
You're throwing a highly adapted neurological system into a sudden freefall. Exactly. Which can trigger severe psychiatric emergencies. What's fascinating here is that the HHS letter actually defends medications in its own text, stating they play an important and sometimes essential role. So the government is raising a flag about getting people off medications, while major medical organizations are warning that doing so incorrectly is lethal.
It's a massive contradiction. So if Washington isn't providing the how-to manual, where do clinicians actually look when a patient is sitting on the exam table asking to taper? Well, since the federal government didn't name a single required guideline, the most robust evidence available right now is the 2026 American Society of Clinical Psychopharmacology or ASCP consensus statement. And that was published in Gemma Network Open, right? Yeah, and the HHS letter actually references it directly.
Lindsay breaks down the specific data from this consensus statement in her article, and it is a fascinating book where experts draw the line. It really is. I mean, this task force had 45 members. And while this is expert opinion rather than a legal standard of tear, they reached at least 75 % agreement on the vast majority of de-prescribing principles. And some of the numbers are practically unanimous.
Like, there was 100 % agreement that clinicians must reassess every single psychotropic medication at least once a year. 100%. Yes. There was also 100 % agreement that you must verify a patient is actually taking their medication before deciding the drug isn't effective. Which highlights a fundamental logic flaw in practice.
You cannot evaluate the efficacy of a chemical that isn't actually in the bloodstream. Right. You'd be surprised how often that gets overlooked. The task force also hit 87 % agreement on discontinuing a drug if there is less than a 25 % drop in overall symptoms. Basically, if it is not providing at least a noticeable partial response, you remove it.
But conversely, 89 % agreed that you should only consider stopping a medication that is working after an extended stretch of sustained remission. Meaning several months to a year of stability. Exactly. You don't pull the plug just because the patient has had a good week. One statistic that really stands out to me is the 96 % agreement to defer de-prescribing if a major life stressor is coming up.
I find that profound. It really shifts the perspective, doesn't it? It does. Because it takes the patient's external environment a divorce, a job loss, a move, and elevates it to an active biological variable. It treats life stress with the same clinical weight as a drug interaction.
It acknowledges that psychiatric stability is a fragile ecosystem. The medication might be the only shock absorber the patient has against that impending stress. Taking it away right before impact is basically clinical malpractice. Okay. But I have to challenge one of the guidelines Lindsay highlights, because it feels completely counterintuitive for a lot of practitioners.
Which one? She points to the inherited patient rule. There was 91 % agreement that, absent obvious toxicity, you should generally hold off on stopping a long-standing drug when you first inherit a new patient. Ah, yes. The inherited patient.
Put yourself in the shoes of an early-career PMH NP. A new patient transfers to your clinic. You open their chart and they're on this messy, illogical regimen of three different overlapping medications prescribed by someone else in 2019. It happens all the time. The immediate burning instinct is to clean up that chart, right?
Strip away the excess and practice elegant, evidence-based medicine right then and there. Oh, that instinct is incredibly powerful. You want to fix the problem immediately, but acting on it during the first few visits is usually a massive mistake. But why? If the regimen makes no pharmacological sense, why leave it in place?
Think of de-prescribing like removing the scaffolding from a decades-old building. You might look at the scaffolding and think, you know, it's ugly, it's unnecessary, and poorly constructed. But until you have thoroughly inspected the foundation, you have no idea if that ugly scaffolding is the only thing keeping the building from collapsing. Wow, that's a great analogy. When you inherit a patient, you do not know their history, their previous hospitalizations, or their unique biology.
So unless the combination of drugs is causing immediate physical danger, like a severe cardiac risk, you have to leave it alone. You have to build clinical trust and investigate the history before you pull a structural support. Ripping away a drug on visit one destroys the therapeutic alliance and risks massive destabilization. Okay, so knowing the theory of when to taper naturally leads to the friction of how you actually have that conversation with a patient, especially when they are reacting to that loud news cycle we discussed earlier. Yeah, and the HHS letter does outline a specific checklist for this consent conversation.
What's on the checklist? You have to cover why the medication is being used, the expected benefits, potential adverse effects, discontinuation symptoms, the probability of relapse, and any evidence-based non-medication options. Let's make this tangible. A patient walks into your clinic tomorrow. They sit down, clearly anxious, and say, I saw on the news that the government says these drugs are overprescribed and dangerous.
I want to stop my sertraline today. Lindsay provides some brilliant practical scripts in her article for this exact moment. The first step is defusing the tension. What does she suggest? She suggests opening with, I'm glad you asked me.
Let's look at your medication specifically because the news can't tell us anything about your unique biology. That is so disarming. It doesn't defend the government and it doesn't dismiss the patient's fear is silly. Right. It just immediately pivots the focus away from Washington DC and back to the patient's own nervous system.
From there, you do the medical history review. But the critical pivot is the safety check. Lindsay recommends telling the patient, please don't stop on your own. Stopping quickly can make you feel physically sick, and it can be incredibly hard to tell that sickness apart from your depression coming back. Separating withdrawal symptoms from disease relapse is vital.
How do you explain the physical sickness part to a patient so they understand the stakes? You explain the mechanics of receptor equilibrium. A drug like sertraline increases available serotonin, and over time, the brain prunes back some of its own receptors to balance things out. Okay. If you abruptly stop the drug, the brain is left with too little serotonin and too few receptors to catch it.
Oh, wow. Yeah. That sudden drought causes electrical misfires in the brain. which patients experience as brain zaps, their literal physical shocks. It causes vertigo, nausea, and intense mood swings.
So by explaining that biological mechanism, you transition a scary national headline into a shared personalized decision. Exactly. You are telling the patient, if we decide to taper, we will slowly lower the dose together so your brain can rebuild those receptors. If I think staying on the medication is safer, I will explain exactly why. The challenge, as any PMHNFP knows, is that safely guiding a patient through that slow receptor rebuild takes an enormous amount of clinical time and monitoring.
Which brings us to a massive logistical hurdle. How does a practitioner actually afford to do this incredibly nuanced work between formal 30-minute office visits? Historically, they haven't been able to. The invisible work of deprescribing reading the patient's portal messages about their brain zaps, reviewing their daily symptom logs, calling the pharmacy to coordinate custom dose holds. All of that happens outside the exam room.
It's all invisible labor. And for decades, the medical system did not compensate providers for that invisible labor, which systemically incentivized rushed care and discouraged complex tapering. Here's where it gets really interesting. The CMS FAQ document actually delivered a massive shift on this front. CMS confirmed that this between-visit invisible work can officially count toward care management billing codes.
Yes. For anyone outside the medical field, this is a fascinating look behind the curtain at how your doctor actually gets paid to keep you safe when you aren't sitting in front of them. It is a structural revelation. Under the Medicare physician fee schedule, this labor is finally recognized as active billable medical management. Lindsay breaks down the exact math for this in her article using CPT code 99484.
which is for general behavioral health integration. Right. To build this code, you need to provide at least 20 minutes of care management in a single calendar month. Here is her real world example. You have a Medicare patient doing a slow taper off sertraline.
Over the month, you spend seven minutes reviewing their PHQ-9, which is the standard depression screening questionnaire, and looking over their symptom log. OK, seven minutes. A week later, you spend nine minutes on the phone with them, managing about a vertigo. Finally, you spend six minutes calling the pharmacy to hold the dose drop and updating the chart. Seven plus nine plus six is 22 minutes.
You have successfully cleared the 20-minute threshold. It transforms uncompensated burnout into sustainable practice, but clinicians must be incredibly careful because CMS enforces strict rules for this billing. What are the specific hurdles to watch out for? Well, first, you cannot just start billing this. A qualifying initiating visit must occur first.
Makes sense. You also need documented patient consent for the care management service, explicitly warning them that cost sharing or co-pays might apply. You must maintain an auditing-proof time log with exact dates and minutes for every action. No estimating. Right.
No estimating. You absolutely cannot double bill this time with Part D medication management codes. And most importantly, this specific FAQ applies only to Medicare. Commercial insurance and state Medicaid plans have wildly different rules, so you have to verify their specific policies. The logic is sound and the compensation is there, but managing those requirements sounds daunting.
How does an early career PMHNP integrate the consent checklists, the yearly reviews, and the new billing tracking into their busy clinic without their entire workflow grinding to a halt? The strength of Lindsay's framework is its pragmatism. You do not need expensive practice consultants or a completely new electronic health record system. She mapped out a 14-day blueprint to upgrade your practice using micro adjustments. Walk us through that two-week blueprint.
Days one to three are dedicated to primary sources. Sit down and read the actual seven pages of the HHS letter and the CMS FAQ. Do not rely on summaries or, you know, deep dives alone. Read the raw text. What about days four to seven?
Days four to seven are about workflow automation. You go into your EHR and add a yearly medication review prompt directly into your standard follow-up template. It should explicitly force you to document that you reviewed the original indication, the side effects, adherence, and discuss the risks of continuing versus tapering. So if it is baked into the template, you won't forget to ask the questions and the documentation happens seamlessly? Exactly.
Then, days 8 to 10 tackle the tapering protocol itself. You need to build a concrete taper plan template. Lindsay makes a vital point here, writing, taper as tolerated in a chart is not a plan, it is a wish. Because taper as tolerated offers zero guidance to a patient suffering from intense vertigo at 9 p .m. on a Saturday.
Right. A functional taper plan requires target milligram doses, an exact timeline, and robust contingency planning. What specific symptoms should trigger the patient to go back to the previous dose. When does a symptom escalate from expected withdrawal to an urgent care visit? Who do they call after hours?
All of that must be templated. That is so practical. And the final step? Days 11 to 14 focus on the reality of the health care network. The HHS guidelines mandate discussing evidence-based non-medication options.
That usually means therapy. But you cannot fulfill that mandate if you have nowhere to send the patient. Precisely. So you spend those four days doing the networking legwork, find two local therapists who actually have current openings, verify their insurance panels, and keep their direct contact info on your desk. That blueprint really takes the overwhelming nature of this policy push and makes it manageable.
And navigating this blueprint highlights exactly why the psych NP fellowship was created. Lindsay Hill designed this 12 month mentorship program for new and early career PMHNPs because reading guidelines is easy but implementing them is incredibly isolating. When you are staring down a patient who is doing surprisingly well on a chaotic combination of three medications, you need a community of experienced clinicians to bounce ideas off of. You shouldn't be making those high stakes calls in a vacuum. With the practice optimized and a support system in place, we need to address the mindset.
Lindsay includes a section titled, What Most People Get Wrong, which exposes the ideological traps practitioners are falling into because of this federal push. There are two opposite but equally dangerous traps. The first is fear-based. Clinicians interpret the federal action plan as a mandate to prescribe less to avoid regulatory trouble. They start instituting blanket dose reductions across their patient panel.
The Dear Colleague letter explicitly warns against blanket reductions. It clearly states that for many patients, continued medication is clearly indicated and life-saving. Exactly. The goal is thoughtful, individualized review, not meeting a quota for getting people off drugs. And the second trap?
The second trap is defiance. Some clinicians look at the political figures spearheading this announcement, find the politics abhorrent, and decide to entirely ignore the deep prescribing guidance out of spite. If a clinician feels this federal push is just political grandstanding, why shouldn't they just ignore it and keep practicing as usual? Because regardless of how a clinician feels about the politics of the announcement, the clinical underlying data is undeniable. Remember that 2026 ASCP consensus?
Right, the 100 % agreement? Yes, 100 % of those experts agreed on the necessity of yearly medication reviews. It is medically indefensible to let a patient coast on a seven-year-old prescription without auditing its effectiveness. Your motivation to review the chart should come from the patient's biology, not from your reaction to a political headline. This brings up one of the most brilliant nuances in Lindsay's article, the paradox of the word overprescribing.
A patient can simultaneously be overprescribed and undertreated. That concept completely changes how you view a patient's chart. Let's unpack that paradox. Imagine a patient taking an antidepressant that completely stopped working three years ago, but they just kept refilling it out of habit. Technically, they are overprescribed.
They are carrying the physical burden and side effects of a chemical that provides zero clinical benefit. Right. But because their original depression is no longer being managed, they are also severely undertreated. So if a practitioner just reads the federal headline, panics and takes the drug away without a comprehensive plan, they have made the patient significantly worse. Vastly worse.
The patient is still undertreated for their depression, but now they are also suffering from withdrawal symptoms. The correct outcome of a medication review isn't always de-prescribing. Sometimes the clinical answer is switching to a different drug, optimizing a dose, or adding an intensive therapy referral. And quite frequently, after reviewing the risks, the benefits, and the lack of viable alternatives, the shared decision between clinician and patient is to simply continue the current medication. That still counts as a successful completed review.
Let's solidify all of this with a rapid-fire FAQ based on the most common questions Lindsay gets. No. The letter introduces no new federal prescribing laws or mandates. Number two. What are the absolute red flags for when a PMHNP should not attempt to deprescribe?
Do not deprescribe if a major life stressor is imminent. Do not deprescribe if you haven't verified the patient is actually taking the medication as prescribed. And do not deprescribe if you have just inherited a patient and haven't fully assessed the historical value of their complex regimen. So if the federal memo isn't a legal mandate, what is actually governing a PMHNP's practice standards today? If we connect this to the bigger picture, it's the exact same authorities that governed your practice last year.
Your state practice act, your state board of nursing, and the peer reviewed clinical standard of care. Those are your authorities. We've covered the history, the biology, the billing, and the guidelines. But theory only matters if it changes your practice. So here is Lindsay's immediate call to action for you this week.
Go into your EHR and pull the charts of your 10 longest-running medication patients. Look closely at their records. Find the last time you documented a comprehensive, explicit risk-benefit review for every single psychotropic drug they take. If it has been over a year for any of them, book that conversation. have the discussion about side effects, efficacy, and their current life stressors.
You will very likely end up keeping most of those prescriptions exactly as they are, but the crucial difference is that now you will have a rock-solid, documented clinical rationale for doing so. And if you are an early-career PMH NP who wants a community to help navigate these complex, high-stakes decisions, look into the Psych NP Fellowship. You do not have to carry the weight of these clinical judgment calls alone. As we wrap up the Steve Dive, I want to leave you with one final provocative thought. It built on everything we've unpacked today regarding how the medical system adapts to pressure.
We are seeing the beginning of a massive systemic shift. If the medical system eventually heavily incentivizes and pays for deep prescribing, how do we ensure that Stopping medications doesn't just become the new unquestioned default. How do we prevent the field from repeating the exact same errors of one size fits all medicine, just in reverse? That is the tightrope every clinician is walking right now. Thank you so much for joining us on this deep dive into the real clinical landscape of deep prescribing.
Remember, just because a political alarm is ringing in the news doesn't mean you have to panic in the exam room. Read the fine print. follow the biology, and keep the patient at the absolute center of every decision. Keep learning and stay curious.
Machine-generated transcript of the AI-voiced audio overview. Also on the Deep Dive podcast.
TL;DR
In this article
One hundred percent. That is how much of a 45-member expert task force agreed that every psychotropic medication should be reassessed at least once a year. Now pull up the patient on your schedule tomorrow who has taken the same three drugs since 2019. When did anyone last ask whether all three still earn their place?
That question landed on the federal agenda on May 4, 2026, when the U.S. Department of Health and Human Services announced an action plan on psychiatric overprescribing. Psychiatric organizations pushed back within days. Six months later, it’s still fair to ask what a new PMHNP is actually supposed to do differently.
Here is the short version: you have no new federal prescribing rule to follow, and that doesn’t leave you with nothing to do. The clinician letter describes a consent conversation worth adopting, CMS has spelled out which between-visit taper work Medicare can pay for, and your patients are hearing about all of this whether or not you bring it up.
This guide covers what was issued, what the evidence supports and the small set of changes worth making in your practice this month.

Three things are on paper. The first is a four-page Dear Colleague letter signed by the leaders of SAMHSA, CMS, HRSA and the Administration for Children and Families. The second is a three-page CMS FAQ on billing for supervised deprescribing. The third is a list of promises, summarized in Psychiatric Times coverage of the plan: a SAMHSA report on prescribing trends, summer webinars, and a July Technical Expert Panel to inform formal HHS clinical guidance on starting, tapering and stopping psychiatric medications.
| Item | Status as of November 1, 2026 | What it means for you |
|---|---|---|
| Dear Colleague letter | Published May 4 | Guidance that encourages. Read it, because patients and payers may quote it. |
| CMS billing FAQ | Dated May 4 | Confirms existing codes can cover taper work. It creates no new code. |
| Formal HHS clinical guidance | This review found no published version | Watch SAMHSA and HHS announcements. Don’t assume what it will say. |
| Panel findings | This review found no published findings | Be skeptical of anyone quoting them. |
Watch the verbs. HHS Secretary Robert F. Kennedy Jr. said the plan would “require informed consent and shared decision-making,” according to Psychiatric Times. The letter itself says HHS “encourages” clinicians and organizations, and it encourages regular review of medication regimens as well. A speech and a letter can carry different weight, and for now the letter is the document you can read and cite.
The letter also says more in medication’s favor than the headlines did. It states that psychiatric medications can play an important and sometimes essential role, and it warns against presenting non-medication options as enough for everyone. It also says deprescribing does not mean abrupt discontinuation or blanket reduction.
The American Psychiatric Association objected to framing the crisis mainly as overprescribing, pointing instead to access barriers and workforce shortages. The American Foundation for Suicide Prevention warned that abrupt or poorly supervised discontinuation can raise relapse and suicide risk. Both concerns belong in your thinking when a patient brings this up.

CMS names no single required guideline. Its FAQ expects evidence-based judgment and points clinicians toward society guidelines, peer-reviewed protocols and FDA labeling. The most useful starting point is the American Society of Clinical Psychopharmacology consensus statement by Goldberg and colleagues, published in JAMA Network Open in 2026. The HHS letter cites it too.
The 45-member task force reached consensus, defined as at least 75% agreement, on 44 of 50 final statements. Treat it as expert opinion. The authors say plainly that it should not be read as a standard of care.
| Situation | What the task force said | Agreement |
|---|---|---|
| Any psychotropic | Reassess at least once a year. | 100% |
| You think a drug failed | Check adherence and whether the trial was adequate before you call it ineffective. | 100% |
| No real response after an adequate trial | Discontinue if the drug hasn’t produced at least a partial response, meaning a 25% or greater drop in overall symptoms. | 87% |
| The drug worked | Consider stopping only after an extended stretch of sustained remission, such as several months or longer. | 89% |
| Major life stress is coming | Defer deprescribing a long-term effective medication. | 96% |
| You just inherited the patient | Absent obvious toxicity, generally hold off on stopping a longstanding drug until you have carefully assessed its value. | 91% |
| Pharmacogenomic report says “caution” | That label alone is not a reason to deprescribe. | 94% |
The inherited patient row matters most for new grads. The urge to clean up a stranger’s regimen in the first visit is strong, and it’s usually a mistake. Our Inherited Diagnoses confidence script gives you language for those early visits.
The statement offers principles, and you won’t find a taper schedule in it. For the how, use a drug-specific plan such as our Hyperbolic Antidepressant Tapering protocol or our Benzodiazepine Taper Protocol, and check current labeling.
The letter lists what a medication discussion should cover at the start of treatment, during it, and when stopping comes up. Turned into a checklist, it reads like this:
None of this is new to a careful clinician. Most of us just cover discontinuation poorly at the start, when it seems far away, and the APA has argued that higher consent standards for psychiatric treatment alone would be stigmatizing. So keep the talk ordinary, the same as you’d have it about any long-term medication.
Expect this visit soon, if you haven’t had it already. A patient opens with: “I saw that the government says these drugs are overprescribed. Should I still be on my sertraline?”
| Moment | What to say | Why it works |
|---|---|---|
| Opening | “I’m glad you asked me. Let’s look at your medication specifically, because the news can’t tell us anything about you.” | Moves from a headline to this patient, without defending or dismissing. |
| Reviewing | “What was going on when you started it? What’s better now? What do you wish was different?” | Gets the real history and any side effects they haven’t mentioned. |
| Safety | “Please don’t stop on your own. Stopping quickly can make you feel sick, and it can be hard to tell that apart from depression coming back.” | Addresses the most immediate risk. |
| Deciding | “Here’s what I’d weigh in your case. If we taper, we’ll pick the timing together and I’ll check on you along the way. If I think staying on it is the better choice, I’ll tell you why.” | Gives your real opinion while keeping the decision shared. |
“Asking whether a medication is still earning its place has always been part of this work. What’s different now is that your patient may have read a headline before they walked in. Have your answer ready, and make sure a taper is never something they start alone.”
Lindsay Hill, DNP, PMHNP-BC
Some patients won’t ask. They will just stop, and you’ll find out months later, if ever. Our script for patients who secretly stop meds covers how to surface that.
Most taper work happens between visits: portal messages, symptom questionnaires, a phone call about brain zaps, a dose hold, a call to the pharmacy. The CMS FAQ names all of those as deprescribing activities and says they can count toward care management codes if every other requirement for the code is met. That last clause is where the work is.
| Code family | Basic shape | Practical fit for a PMHNP |
|---|---|---|
| General BHI (99484) | At least 20 minutes per calendar month of care management for a behavioral health condition, with monitoring, care planning and an ongoing care team contact. | Often the closest fit. CMS’s January 2026 booklet (MLN909432) lists nurse practitioners and mentions psychiatry, and the billing practitioner may deliver the service in full. |
| CCM (99490, 99491 and add-ons) | Two or more chronic conditions expected to last at least 12 months. 99491 needs at least 30 minutes of your own time, and clinical staff codes start at 20. | Possible for patients with qualifying comorbid conditions, if you actually run the care plan and other required elements. |
| PCM (99424 to 99427) | Care management focused on a single high-risk condition. | CMS mentions these codes for regimens needing frequent adjustment. Check the descriptor against your patient before using them. |
| Psychiatric CoCM (99492 to 99494) | A primary care team model with a care manager, a psychiatric consultant and a registry. | This belongs to integrated primary care. It’s rarely workable for a solo psychiatric practice. |
Here is what a month could look like. A Medicare patient is on a slow sertraline taper. You spend 7 minutes reviewing a PHQ-9 and a symptom log, 9 minutes on the phone about dizziness, and 6 minutes holding the dose and updating the plan with the pharmacy. That’s 22 minutes, which clears the 99484 threshold, provided the rest of the requirements are in place.
Before billing any of it, confirm these:
The FAQ applies only to the Medicare Physician Fee Schedule. The letter’s own footnote tells clinicians that state Medicaid and CHIP coverage varies, even for the psychotherapy and nutrition codes it lists. So check with each commercial plan and state program, and take unclear Medicare questions to your Medicare Administrative Contractor. Cash-pay practices have none of this to worry about, though the clinical work is the same.
None of this requires a new EHR or a consultant. Two weeks of small changes will cover it.
Days 1 to 3. Read the letter and the FAQ yourself. Together they are seven pages plus references.
Days 4 to 7. Add a yearly medication review prompt to your follow-up template:
Annual medication review: Reviewed indication, current benefit, adverse effects and adherence for each psychotropic. Discussed continuing vs tapering, discontinuation symptoms, relapse risk and non-medication options. Patient prefers ____. Plan: ____.
Days 8 to 10. Build a taper plan template using the elements CMS lists: the schedule, target doses, what you’ll do if symptoms come back, when to seek urgent care and who gets told about dose changes. A plan that only says “taper as tolerated” won’t help anybody at 9 p.m. on a Saturday.
Days 11 to 14. Line up referrals. You can’t offer non-medication options honestly without somewhere to send people, so name two therapists who actually have openings and keep them on file. While you’re at it, keep a dosing reference handy, such as our free prescribing cheat sheet.
Deciding when to taper is hard to learn from a document, particularly for a patient who is doing well on three drugs nobody can fully explain. The Psych NP Fellowship is a 12-month clinical mentorship for new and early-career PMHNPs who want to talk through cases like that with experienced clinicians.
The common reading is that the federal plan is a verdict: prescribe less, or expect trouble. The letter doesn’t say that. It describes an individualized decision, says continued medication remains clearly indicated in some cases, and warns against stopping in ways that damage safety or trust.
The opposite mistake is just as common. Clinicians who dislike the politics may decide they can ignore all of it. But a yearly review has task force support at 100%, and it’s hard to defend skipping one for a patient who has been on the same regimen for seven years. Your reasons for that review should come from the patient in front of you, whatever you think of the announcement.
The word “overprescribing” can mislead too. A patient who stopped responding to a drug years ago may be overprescribed and undertreated at once. Taking the drug away without offering anything else would leave them no better off. Often the honest result of a review is a switch, a dose change or a therapy referral. Sometimes it’s a documented decision to continue, and that counts as a finished review too.

No federal prescribing requirement appears in the May 4, 2026 Dear Colleague letter, which encourages clinicians to act. Your state practice act, your board and the clinical standard of care still govern what you do. Formal HHS guidance may follow, so check for updates.
Yes, when all the requirements of the code are met. CMS says taper work can count as time under care management codes, and its behavioral health integration booklet lists nurse practitioners among those who may bill. Commercial and Medicaid rules vary, so confirm with each payer.
At least once a year, according to the 2026 American Society of Clinical Psychopharmacology task force, which reached 100% agreement on that statement. Many patients need more frequent review, especially during a taper or after a change in health or life circumstances.
Wait when a major life stressor is coming, when you have not checked adherence or whether the trial was adequate, or when you have just inherited the patient and have not yet judged the drug’s value. Those exceptions all come from the same task force. Obvious toxicity is a different situation and needs action now.
Thank them for raising it, ask them not to stop on their own, and book a real review of the medication. Explain that stopping suddenly can bring discontinuation symptoms and that relapse is a separate risk. If a taper makes sense, build it together and set up check-ins.
Federal guidance on tapering may arrive next month or next year, and it may look different from what anyone expects. You don’t need to wait for it to start reviewing medications well. The consent checklist and the yearly review are worth doing on their own.
So start with one list this week. Pull your 10 longest-running medication patients and check the chart for the last documented risk-benefit review of each drug. Book that conversation for anyone who hasn’t had one in a year. You’ll keep most of those prescriptions, and you’ll know why.

Don’t make the hard prescribing calls alone
The Psych NP Fellowship is a 12-month clinical mentorship program for new and early-career PMHNPs, with live coaching and a peer community.
This content is for educational purposes and does not replace individualized clinical judgment or supervision.
About the author: Lindsay Hill, DNP, PMHNP-BC is the founder of the Psych NP Fellowship, a 12-month clinical mentorship program for new and early-career psychiatric nurse practitioners. She is a published contributor to Psychiatric Times, past President of the Arizona APNA Chapter, and co-founder of the Psych NP Network.
The Psych NP Fellowship Team provides evidence-based clinical content, prescribing insights, and career guidance for new and early-career psychiatric nurse practitioners. Led by Lindsay Hill, DNP, PMHNP-BC, the team is dedicated to bridging the gap between PMHNP education and confident clinical practice.
Weltruza, the first monthly subcutaneous olanzapine LAI, drops the 3-hour observation. What PMHNPs need on dosing, PDSS, candidates, and metabolic monitoring.
Read More →
The first US adult ADHD guidelines are due this fall, and the DEA telehealth deadline hits Dec 31. What PMHNPs should tighten in adult ADHD practice now.
Read More →
Grad PLUS is gone and nursing lost professional-degree status, capping loans at $20,500 a year. What the RISE rule and court fight mean for PMHNPs in 2026.
Read More →Book a free 20-minute call with our team, or join the Psych NP Fellowship today: $297/mo for 12 months, or $2,997 paid in full.
Talk to Our TeamSecure checkout by Stripe. After you pay, we invite you to Skool, the app where we meet.